|
|
|
|
| LEADER |
01886nam a2200349 u 4500 |
| 001 |
EB001999823 |
| 003 |
EBX01000000000000001162724 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Islam, Saadul
|
| 245 |
0 |
0 |
|a Prostaglandin analogues for ophthalmic use
|h Elektronische Ressource
|b a review of comparative clinical effectiveness, cost-effectiveness, and guidelines
|c Saadul Islam, Carolyn Spry
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, February 18, 2020
|
| 300 |
|
|
|a 1 PDF file (46 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Glaucoma / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Prostaglandins, Synthetic / therapeutic use
|
| 653 |
|
|
|a Ocular Hypertension / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Guidelines as Topic
|
| 653 |
|
|
|a Intraocular Pressure
|
| 700 |
1 |
|
|a Spry, Carolyn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK562924
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a n 2015, CADTH prepared a Rapid Response Summary with Critical Appraisal on the clinical effectiveness and cost-effectiveness of BIM compared with other PGAs for ophthalmic use. The objective of the current report is to evaluate the evidence published as of 2015 on the clinical effectiveness and cost-effectiveness of BIM versus other PGAs for ophthalmic use. Additionally, evidence-based guidelines regarding the use of BIM for elevated intraocular pressure will be reviewed
|